Clinical Trials
22 trialsNCT06788509 2026-06-05
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT03424122 2025-08-21
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
Phase 1 Completed
NCT04876092 2025-08-21
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Janssen Research & Development, LLC
Phase 1 Completed
NCT03400176 2025-05-16
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Novartis
Phase 1 Terminated
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT04274738 2024-08-27
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
X4 Pharmaceuticals
Phase 1 Completed
NCT02352558 2023-11-14
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03876028 2023-01-31
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Novartis
Phase 1 Terminated
NCT02954406 2022-02-18
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Takeda
Phase 1 Terminated
NCT01644253 2021-05-20
Phase 1b Safety and Efficacy Study of TRU-016
Aptevo Therapeutics
Phase 1 Terminated
NCT02759016 2020-09-29
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Boehringer Ingelheim
Phase 1 Completed
NCT03301207 2019-12-05
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
Janssen Research & Development, LLC
Phase 1 Completed
NCT02006485 2019-11-05
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT02556892 2019-08-14
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT02973399 2019-02-22
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Esanex Inc.
Phase 1 Terminated
NCT02914327 2018-07-30
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Esanex Inc.
Phase 1 Withdrawn
NCT01704963 2018-02-05
A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT02381080 2017-06-26
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Janssen Research & Development, LLC
Phase 1 Completed
NCT02780830 2016-09-15
INHIBITOR
AstraZeneca
Phase 1 Withdrawn
NCT01674322 2014-11-05
A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Janssen Research & Development, LLC
Phase 1 Completed
NCT01292135 2014-07-24
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
Phase 1 Completed
NCT00849654 2013-05-22
PCYC-04753
Pharmacyclics LLC.
Phase 1 Completed